Diagnosys is proud to announce that the USPTO has patented another one of our inventions! Our Electrically Evoked Response (EER) Stimulator/Amplifier Combination earned US patent 11,497,911 on Nov 15th 2022.
The EER apparatus stimulates and records electrical responses at the same time, utilizing a new design which both sends a current to the eye and records the current from the patient’s eye, measuring recordings from either the retina or the visual cortex.
EER is currently being used in circumstances where light cannot be used as a stimulus to assess the salvageability of the eye. In cases of trauma where the globe is filled with blood, the visual system can be electrically stimulated to assess visual pathway integrity.
In recent efforts, EER has been used on patients with no light perception (NLP) to screen candidates for regenerative therapies. In cases where vision may be restored by regenerating photoreceptors, the post-photoreceptor pathways must be assessed to qualify patients for the trial.
By integrating the stimulator with the amplifier/data acquisition system, our design perfectly synchronizes the delivery of an electric pulse with the recording of a bioelectrical signal. This is unlike existing systems which perform the two functions through two separate units, requiring two separate eye electrodes. Our EER module utilizes the standard DTL thin fiber corneal electrode.
To accomplish this engineering feat, our designers have taken great precautions to ensure the patient’s safety during EER stimulation. The duration and amplitude of the applied current are controlled with great precision while the current source is monitored before and during stimulation to 100% verify that the correct stimulus is being applied.
With this humble brag, we are delighted to introduce our EER for use in novel research and applications towards the betterment of human vision. The EER is registered for human clinical use in the EU and Japan. Please note that EER is not currently FDA approved for clinical use, but can be used for animal research and under IRB approval at institutions in the US.